Endocrine Abstracts

Background: To determine whether radioiodine remnant ablation (RRA) reduces cause-specific mortality (CSM) or tumor recurrence (TR) rates after bilateral thyroidectomy (BT) in low-risk adult papillary thyroid carcinoma (APTC) patients treated with curative intent, we compared outcome in 1836 stage I patients having BT alone with 832 having BT+RRA.Methods: THEN cohort (1966-1990) comprised 809 patients; 36% having RRA within 6 postoperative months. NOW co...

Objectives: Childhood papillary thyroid cancer (CPTC) often presents with advanced disease but rarely results in cause-specific mortality (CSM). Controversy remains regarding optimal management and association with non-thyroid second primary malignancies (NSPM). We analyzed outcome in 189 CPTC patients and assessed the influence of radioiodine remnant ablation (RRA) and the utility of the American Thyroid Association risk-groups (ATA-R) in predicting tumor recurrence (TR)....

Introduction: Childhood papillary thyroid carcinoma (CPTC), despite bilateral thyroidectomy (BT), nodal resection and radioiodine remnant ablation (RRA), recurs within neck nodal metastases (NNM) in >30% within 20 postoperative years. However, these NNM are usually treated with re-operation or further radioiodine; US-guided ethanol ablation (EA) may be considered (j.sempedsurg.2020.150920) for patients with limited numbers of NNMMethods: We studied l...

Context: Phaeochromocytomas are rare, but potentially fatal, neoplasms. The diagnosis and localization of phaeochromocytoma can be challenging and recently there has been some debate regarding the role for adrenal venous sampling (AVS). The utility of AVS in this setting is hampered by a lack of normative value data for adrenal vein catecholamine concentrations and the reliability of lateralization ratios. We sought to address these concerns by analyzing AVS catecholamine conc...

The study aims were to characterize patients with papillary thyroid microcarcinoma (PTM) and to provide data on long-term outcome. About 900 patients with PTM (tumor size 1 cm or less) had treatment at our centre during 1945–2004. Follow-up extended to 54 years. Mean follow-up for 638 survivors was 13.5 years. Recurrence and mortality details were derived from a computerized database. Median tumour size was 7 mm. About 99% of tumors were grade 1; 98% were not locally inva...